RingelMD, SosaJA, BalochZ, et al.2025 American thyroid association management guidelines for adult patients with differentiated thyroid cancer. Thyroid2025;35(8):841-985; doi: 10.1177/10507256251363120.
2.
CarrAL, GabrielKL, PillaiG, et al.Patient perspectives toward a decision aid for radioactive iodine treatment for intermediate risk thyroid cancer. Int J Behav Med. Epub2025; doi: 10.1007/s12529-025-10408-4.
3.
RuelE, ThomasS, DinanM, et al.Adjuvant radioactive iodine and survival in intermediate-risk papillary thyroid cancer. J Clin Endocrinol Metab2015;100(4):1529-1536; doi: 10.1210/jc.2014-4332.
4.
SawkaAM, StrausS, RotsteinL, et al.Randomized controlled trial of a computerized decision aid on adjuvant radioactive iodine treatment for patients with early-stage papillary thyroid cancer. J Clin Oncol2012;30(23):2906-2911; doi: 10.1200/JCO.2011.41.2734.
5.
KarciogluAS, DhillonVK, DaviesL, et al.Analysis of unmet information needs among patients with thyroid cancer. JAMA Otolaryngol Head Neck Surg2023;149(2):110-119; doi: 10.1001/jamaoto.2022.4108.
6.
LeeEK, KimMJ, HwangboY, et al.Shared Decision-Making for Determining Treatment Strategies in Low-Risk Thyroid Cancer: Protocol of a Multicenter Cluster-Randomized Trial (MAeSTro-SDM). J Korean Med Sci2026;41(4):e58; doi: 10.3346/jkms.2026.41.e58.
